Background: Recent technological advancements have revolutionized our approach to healthcare, enabling us to harness the potential of smartphones and wearables to collect data that can be used to characterize Alzheimer's disease (AD) heterogeneity and to develop digital biomarkers. Our focus is to create comprehensive cross-domain digital datasets and establish an infrastructure that allows for seamless data sharing. Central to accelerating the potential of digital biomarkers for more accurate and early detection is privacy-protecting data access, which when combined with deep molecular phenotyping, will enhance our understanding of the biological mechanisms underlying clinical expression.
Methods: In the preliminary phase of this project, we analyzed data from 64 participants from the Boston University Alzheimer's Disease Research Center and encompassing approximately 1480 variables. Our analysis approach leverages a novel machine learning (ML) technology, Attractor AI, that is capable of differentiating causal and non-causal subpopulations within small patient or study populations and large volumes of measures, enhancing the efficacy of predictive models.
Results: We were able to subcategorize 50% of the 27 cognitively impaired (CI) subjects. A notable discovery was a distinct subpopulation of 8 individuals, 7 of whom were CI, characterized significantly by higher sleep-derived variables such as various desaturation thresholds and periodicity measures (p=0.008-0.00007). Additionally, incorporating maximum heart rate, revealed another group of 8 subjects, 6 identified as CI, distinguished by elevated heart rate during one or more of their measuring instances (p=10).
Conclusions: While these results are preliminary, they signal a promising direction to cluster subgroups of people along similar dimensions, laying the groundwork for a precision medicine solution. Our future endeavors include expanding the scope of multimodal digital data to encompass aspects like vocalization and speech patterns derived from cognitive assessments, gait analysis, physical activity, and other cognitive tests. The integration of these diverse data streams, coupled with our preliminary sleep analysis findings, has the potential to result in a robust and accurate subgrouping system for CI to help identification of AD risk pathways that might be amenable to early intervention and either delay or prevent potential transition to AD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.093236 | DOI Listing |
Mol Neurodegener
January 2025
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer's disease and other neurodegenerative diseases. While a number of TREM2 ligands have been identified, little is known regarding the structural details of how they engage. To better understand this, we created a protein library of 28 different TREM2 variants that could be used to map interactions with various ligands using biolayer interferometry.
View Article and Find Full Text PDFFluids Barriers CNS
January 2025
Sanders-Brown Center on Aging, College of Medicine, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA.
Background: Blood-brain barrier dysfunction is one characteristic of Alzheimer's disease (AD) and is recognized as both a cause and consequence of the pathological cascade leading to cognitive decline. The goal of this study was to assess markers for barrier dysfunction in postmortem tissue samples from research participants who were either cognitively normal individuals (CNI) or diagnosed with AD at the time of autopsy and determine to what extent these markers are associated with AD neuropathologic changes (ADNC) and cognitive impairment.
Methods: We used postmortem brain tissue and plasma samples from 19 participants: 9 CNI and 10 AD dementia patients who had come to autopsy from the University of Kentucky AD Research Center (UK-ADRC) community-based cohort; all cases with dementia had confirmed severe ADNC.
Alzheimers Res Ther
January 2025
Laboratory for Clinical Neuroscience, Center for Biomedical Technology, Universidad Politécnica de Madrid, IdISSC, Crta M40, km38, Madrid, 28223, Spain.
Background: Dementia patients commonly present multiple neuropathologies, worsening cognitive function, yet structural neuroimaging signatures of dementia have not been positioned in the context of combined pathology. In this study, we implemented an MRI voxel-based approach to explore combined and independent effects of dementia pathologies on grey and white matter structural changes.
Methods: In 91 amnestic dementia patients with post-mortem brain donation, grey matter density and white matter hyperintensity (WMH) burdens were obtained from pre-mortem MRI and analyzed in relation to Alzheimer's, vascular, Lewy body, TDP-43, and hippocampal sclerosis (HS) pathologies.
Commun Biol
January 2025
Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.
Brain organoid models have greatly facilitated our understanding of human brain development and disease. However, key brain cell types, such as microglia, are lacking in most brain organoid models. Because microglia have been shown to play important roles in brain development and pathologies, attempts have been made to add microglia to brain organoids through co-culture.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!